Akebia Therapeutics Inc (AKBA) concluded trading on Thursday at a closing price of $1.69, with 9.6 million shares of worth about $16.23 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 14.19% during that period and on March 13, 2025 the price saw a loss of about -12.44%. Currently the company’s common shares owned by public are about 211.54M shares, out of which, 209.23M shares are available for trading.
Stock saw a price change of -11.98% in past 5 days and over the past one month there was a price change of -19.52%. Year-to-date (YTD), AKBA shares are showing a performance of -11.05% which increased to 17.36% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.80 but also hit the highest price of $2.48 during that period. The average intraday trading volume for Akebia Therapeutics Inc shares is 2.25 million. The stock is currently trading -10.55% below its 20-day simple moving average (SMA20), while that difference is down -15.77% for SMA50 and it goes to 6.22% higher than SMA200.
Akebia Therapeutics Inc (NASDAQ: AKBA) currently have 211.54M outstanding shares and institutions hold larger chunk of about 28.71% of that.
The stock has a current market capitalization of $368.73M and its 3Y-monthly beta is at 0.86. It has posted earnings per share of -$0.22 in the same period. It has Quick Ratio of 1.21. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for AKBA, volatility over the week remained 7.90% while standing at 5.47% over the month.
Stock’s fiscal year EPS is expected to rise by 24.24% while it is estimated to increase by 140.00% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by BTIG Research on November 29, 2023 offering a Buy rating for the stock and assigned a target price of $4 to it. Coverage by H.C. Wainwright stated Akebia Therapeutics Inc (AKBA) stock as a Buy in their note to investors on August 28, 2023, suggesting a price target of $3.75 for the stock. On May 31, 2023, Piper Sandler Upgrade their recommendations, while on March 31, 2022, Piper Sandler Downgrade their ratings for the stock with a price target of $2. Stock get a Hold rating from Needham on March 31, 2022.
